

Blood Test Kit for Early Evaluation of Neuro-Immune Imbalance- Anxiety / PTSD Diagnosis Kit (Yissum) code: 7-2006-385

[Hermona Soreq](#), HUJI, Faculty of Science, The Alexander Silberman Institute for Life Sciences

Categories	Biotechnology- Diagnosis, Homeland Security
Development Stage	Proof of concept established; seeking commercial partner
Patent Status	Patent applied for in Us. Europe, Canada, Australia, Israel and Singapore
Market Size	About 3.6 percent of U.S. adults ages 18 to 54 (5.2 million people) have PTSD during the course of a given year.

Highlights

- Novel biochemical approach to the diagnosis of anxiety associated disorders
- Objective, accurate test for post traumatic stress disorder (PTSD) and other Anxiety disorders
- Quantified acetylcholine regulation parameters for assessing treatment efficacy
- Kit consists of a multi-well plate and reagents.
- Cholinergic status of patient read by a standard ELISA reader and calculated by an available set of equations

Our Innovation

Blood test for biochemical parameters reflecting the specific cholinergic related enzymatic activity in the circulation was substantiated by comparison with population baseline database of Anxiety diagnosis questionnaire results. The blood test enables reliable prediction of trait and state anxiety measures.

Key Features

- Provides early and objective diagnosis of anxiety and PTSD risk without need to rely on patient subjective reports.
- Provides objective evaluation of the efficacy of Anxiety treatment
- Can be used for specific neurological patient groups with defined anxiety-associated symptoms, such as hypersensitivity, depression or cognitive deterioration, for predicting future recovery prospects under various treatment paradigms

Development Milestones

- Broadening scope for detection of treatment efficacy
- Seeking strategic partner for development and commercialization

The Opportunity

In the United States, roughly 3.6 days of work impairment per month associated with PTSD translates into an annual productivity loss in excess of \$3 billion

Contact for more information:

Shoshana Keynan , VP, Head of Business Development, Healthcare, +972-2-6586683

Yissum Research Development Company of the Hebrew University of Jerusalem
Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem P.O. Box 39135, Jerusalem 91390
Israel Telephone: 972-2-658-6688, Fax: 972-2-658-6689